Enveda Biosciences will enter the clinic next year with at least one of its three main programs thanks to a $68 million boost in financing — about $55 million via equity and the remainder debt.
Founded by an early employee at AI startup Recursion Pharmaceuticals, Enveda has adjusted its priorities since disclosing a $51 million Series A in June 2021. At the time, CEO Viswa Colluru told Endpoints News the three core areas were Wilson disease, NASH and Parkinson’s.
Now, three relatively new programs are progressing in tandem, Colluru told Endpoints in a preview of the Series B, which was announced Wednesday but closed a few months ago. On deck are molecules that modulate the inflammasome pathway; non-opioid oral and topical analgesics for pain…
Click here to view original post
